Paul M. Beer., M.D.
Naomi S. Falk, O.D., M.D.
Pawan Bhatnagar, M.D.
Fatima Ahmed, M.D.
Sabah Shah, M.D.

...................................................................................................................................................................................................................................

 


This page showcases some of the various clinical trials that we have been involved with, bringing state of the art technologies and pioneering treatments to the people of New York's Capital District and surrounding region.

We are currently enrolling patients in clinical trials with macular degeneration, diabetic retinopathy, macular edema and several other conditions. Upcoming studies, pending various approvals, will soon be enrolling patients with macular edema, uveitis, ocular inflammation, and other conditions.

 

Macular Degeneration

 

RACE

Enrollment Open

July 2010

Macular Degeneration
This trial involves:
  • 2 drugs injected into an eye
  • A phase I study to evaluate the safety of anti-Complement (AL-78898A)  Injections in addition to Lucentis
    OPH1001

    Enrollment Open

    April 2010

    Macular Degeneration
    This trial involves:
  • 2 drugs injected into an eye
  • A phase II study to evaluate the safety of anti-PDGF (E10030)  Injections in addition to Lucentis
    INSURE

    Enrollment Open

    April 2010

    Noninfectious Intermediate, Posterior or Panuveitis

    This trial involves:

  • a drug injected into in the vein
  • Dose-ranging phase III trial to assess a monoclonal antibodies to IL 17 (IN457 vs. Placebo)
    ForeseeHome Device Study

    Enrollment Open

     May 2010

     

    Macular Degeneration
    This trial involves:
  • a non invasive home monitoring device 

  • A non invasive device to detect conversion to neovascular AMN
    OPH3000

    COMPLETED

    2008-2009

    Macular Degeneration
    This trial involves:
  • 2 drugs injected into an eye
  • A phase I study to evaluate the safety of Volociximab Injections in addition to Lucentis

    INTRAVITREAL

    REMICADE

    COMPLETED

    2008

    Macular Degeneration & Diabetic Retinopathy
    This trial involves:
  • a drug injected into an eye
  • A phase I-pilot study to evaluate the safety of intravitreal Remicade (Infliximab) Injections for patients with severe diabetic macular edema or choroidal neovascularization

    OPH1000

    COMPLETED

    2007-2008

    Macular Degeneration
    This trial involves:
  • 2 drugs injected into an eye
  • A phase I study to evaluate the safety of anti-PDGF Injections in addition to Lucentis
    Regeneron

    View 1

    COMPLETED

    2007-2008

    Wet Macular Degeneration This Trial involves:
  • a drug injected into an eye
  • Phase 3 study to evaluate the VEGF Trap for wet Macular Degeneration

    AIN457

    Open

    2007-2008

    Non-infectious Uveitis
    This trial involves:
  • a drug injected into in the vein
  • Phase 2 study to evaluate monoclonal antibodies to IL 17 for uveitis

    AREDS2

     OPEN

    2006-2011

     

    Dry Macular Degeneration
    This trial involves:

  • lutein, zeaxanthin, omega-3 fatty acids
  • Prevention of age related macular degeneration and cataracts with vitamin supplementation

    Sponsored by the National Institute of Health

    SALVAGE

    COMPLETED

    Study Ongoing

    2006-2008

    Macular Degeneration
    This trial involves:
  • a drug injected into an eye
  • A phase I/II study to evaluate Scotoma reduction and Limited Visual Acuity in a GE related macular degeneration.

    Patients treated with LUCENTIS

    HORIZON
    FVF3426

    COMPLETED

    Macular Degeneration
    This trial involves:
  • a drug injection into an eye
  • Open label extension study with LUCENTIS (rhuFab V2) Therapy for Anchor and Marina patients

    SAILOR

    COMPLETED

    Macular Degeneration
    This trial involves:

  • a drug injected into an eye
  • Open label study with LUCENTIS (rhuFab V2> Therapy for Age Related Macular Degeneration

    MARNIA
    COMPLETED

    Macular Degeneration
    This trial involves:

  • A drug injected into an eye
  • A drug injected to an arm vein
  • laser treatment to the eye
  • Ranibizumab (rhuFab V2) Therapy for patients with Minimally Classic Subfoveal Choroidal Neovascular Membranes secondary to Macular Degeneration

    ANCHOR

    COMPLETED

    Macular Degeneration This Trial involves:

  • a drug injected into an eye
  • a drug injected into an arm vein
  • laser treatment to the eye
  • Ranibixumab (rhuFab V2) or Verteporfin (visudyne) Therapy for Patients with Mostly Classical Subfoveal Choroidal Neovascular Membranes secondary to Macular Degeneration

    PFIZER

    COMPLETED

    Macular Degeneration
    This trial involves:

  • a drug injected next to the eye
  • Phase I anti-VEGF therapy

    Subfoveal Choroidal Neovascular Membranes secondary to Macular Degeneration

    EYETECH


    COMPLETED

    Macular Degeneration
    This trial involves:

  • A drug injected into the eye
  • Macugen
    Compassionate Use for

    Patients with Wet Macular Degeneration

    VIO

    COMPLETED
    Macular Degeneration
    This trial involves:
  • a drug injected into an arm vein
  • laser treatment to the eye
  • Vereporfin (Visudyne) Therapy for Patients with Entirely Occult Subfoveal Choroidal Neovascular Membranes secondary to Macular Degeneration
    ADD-V

    COMPLETED
    Macular Degeneration
    This trial involves:
  • a drug injected into an arm vein
  • eye drops

  • Vereporfin (Visudyne) and Voltaren drops Therapy for Patients with  Subfoveal Choroidal Neovascular Membranes secondary to Macular Degeneration

     

    Diabetic Retinopathy

     


    INTRAVITREAL

    REMICADE

    COMPLETED

    2008

    Macular Degeneration & Diabetic Retinopathy
    This trial involves:
  • a drug injected into an eye
  • A phase I/pilot study to evaluate the safety of intravitreal Remicade (Infliximab) Injections
    RISE
    FVF4168g


    Enrollment
    Closed
    Diabetic Retinopathy
    This Trial Involves:
  • an oral drug taken daily
  • Intravitreal injections of Ranibizumab administered monthly for 24 months for patients with Diabetic Macular Edema
    LILY ARXXANT
    B7A-MC-MBCU

    COMPLETED

    2006-2008
    Diabetic Retinopathy
    This trial involves:
  • an oral drug taken daily
  • Ruboxistaurin for Macular Edema in patients with Diabetes Mellitus

    Assesed by Optical Coherence Tomography

    Completed Diabetic Retinopathy
    This trial involves:
  • a drug injected into the eye
  • Intravitreal Steroid for diabetic Macular Edema Laser for Diabetic Macular Edema
    Completed Diabetic Retinopathy
    This trial involves:
  • a drug injected into the eye
  • Modified Grid or Focal Laser for Diabetic Macular Edema
    Completed Diabetic Retinopathy
    This trial involves

  • A drug injected into the eye
  • OCT for Diabetic Macular Edema

     

    Central Retinal Vein Occlusion

    STUDY CLOSED

    Retinal Vein Occlusions
    This trial involves:
  • a drug releasing implant injected into an eye
  • Intravitreal Steroid Implant for Vein Occlusions with Macular Edema
    ...................................................................................................................................................................................................................................


    Home | Our Doctors | Clinical Trials | Emergency Contact | Office Locations | Office Images

    Eye Information | Eye Diseases | Genetic Testing


    Retina Consultants
    1220 New Scotland Rd., Suite 201
    Slingerlands, NY 12159
    Voice:(518) 533-6550
    Fax:(518)533-6556